What Is Ipamorelin? Definition and What Research Reports

Ipamorelin: the short definition

Ipamorelin is a synthetic pentapeptide — a chain of five amino acid residues, commonly written Aib-His-D-2-Nal-D-Phe-Lys-NH₂ — that belongs to the pharmacological class called growth hormone secretagogues (GHS). It is not a hormone that occurs naturally in humans or animals; it was designed in the laboratory as part of a series of small peptides intended to act at the growth hormone secretagogue receptor 1a (GHS-R1a), the receptor for the stomach-derived hormone ghrelin. Because it engages that receptor, published papers routinely describe it as a "ghrelin mimetic," the exact phrase used in a 2009 rodent study of ipamorelin in postoperative ileus (J Pharmacol Exp Ther, 2009). This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or substance.

Where the name and the molecule come from

The -relin ending follows the naming convention used for compounds that act on growth hormone release — a family that also includes sermorelin, hexarelin and anamorelin. Ipamorelin and anamorelin are frequently grouped together in the literature as GHS-R1a agonists; both were tested side by side in a 2024 ferret study of chemotherapy-associated weight loss (Physiol Behav, 2024). Ipamorelin is manufactured by peptide synthesis rather than extracted from tissue, and, like many research peptides, it is often handled as an acetate salt — the form named in a 2024 study in the cichlid fish Oreochromis mossambicus (Anim Reprod Sci, 2024).

How the term is used in peptide research

In scientific writing, "ipamorelin" is used in three fairly consistent ways:

• As a class member. It appears in lists of GHS-R1a agonists alongside ghrelin itself, GHRP-6, hexarelin and anamorelin. Ipamorelin and GHRP-6 were compared directly in adult female rats in a 2000 bone study (J Endocrinol, 2000).
• As a pharmacological tool. Investigators use it to probe what happens when the ghrelin receptor is stimulated in a particular tissue or model — for example, pituitary somatotroph behaviour assessed in vitro after chronic treatment of young female rats (Histol Histopathol, 2002).
• As a candidate intervention in a disease model. Most published work sits here: bone loss, gut motility, insulin secretion, and cancer-treatment-associated weight loss.

It is also worth separating ipamorelin from a different class it is often shelved next to. GHRH analogues (such as sermorelin or tesamorelin) act at the growth hormone-releasing hormone receptor; ipamorelin acts at the ghrelin receptor. Papers keep that distinction, and readers of the literature will find the two classes described with different mechanisms even when the endpoint studied is similar.

What the published literature reports

Bone endpoints in rats

Two rodent papers form much of the early skeletal literature. Researchers reported that ipamorelin and GHRP-6 increased bone mineral content in adult female rats in a 2000 study (J Endocrinol, 2000). A follow-up line of work reported that ipamorelin counteracted a glucocorticoid-induced decrease in bone formation in adult rats (Growth Horm IGF Res, 2001). Both were animal experiments using laboratory models of bone turnover, not clinical osteoporosis trials.

Pituitary somatotrophs

Chronic administration of ipamorelin to young female rats was examined for its effect on the somatotroph population of the pituitary, with the study assessing somatotroph responsiveness in vitro after treatment (Histol Histopathol, 2002). That design speaks to how repeated receptor stimulation influences the growth-hormone-producing cells themselves.

Gastrointestinal transit

Ghrelin-receptor agonism has been studied as a prokinetic strategy. The study in a rodent model of postoperative ileus evaluated ipamorelin's efficacy on impaired gastrointestinal transit after abdominal surgery and described the compound as a novel ghrelin mimetic (J Pharmacol Exp Ther, 2009).

Insulin release

A 2004 paper examined the mechanism by which ipamorelin evoked insulin release from the pancreas of normal and diabetic rats, placing the peptide in the broader discussion of how ghrelin-receptor signalling intersects with islet function (Neuro Endocrinol Lett, 2004).

Weight loss in a chemotherapy model

In ferrets given cisplatin, researchers reported that the GHS-R1a agonists anamorelin and ipamorelin inhibited cisplatin-induced weight loss, while anamorelin — and not ipamorelin — additionally showed anti-emetic effects attributed to a central mechanism (Physiol Behav, 2024). That divergence is a useful reminder that compounds sharing a receptor target do not necessarily share every downstream effect.

Reproductive axis in a non-mammalian model

A 2024 study investigated the influence of ipamorelin acetate on the hypothalamic-pituitary-testicular axis in the cichlid fish Oreochromis mossambicus, extending ghrelin-receptor research into comparative endocrinology (Anim Reprod Sci, 2024).

Human research

The clinical literature is thin. A prospective, randomized, controlled, proof-of-concept study evaluated the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (Int J Colorectal Dis, 2014). The label "proof-of-concept" is the authors' own and signals an early-phase design rather than a definitive efficacy trial.

Study models at a glance

Safety and Tolerability: What Studies Report

The verified literature summarised here is not a safety database, and none of these papers is a long-term toxicology programme. The only controlled human work identified is the randomized, placebo-controlled proof-of-concept trial in bowel resection patients, which was conducted under a formal trial design with monitoring (Int J Colorectal Dis, 2014). Endpoints elsewhere that would be relevant to any safety discussion include the insulin release evoked in normal and diabetic rats (Neuro Endocrinol Lett, 2004) and the reproductive-axis effects examined in fish (Anim Reprod Sci, 2024) — both illustrate that ghrelin-receptor stimulation reaches systems beyond growth hormone. Because most of the record is preclinical, the published evidence does not establish a human adverse-event profile.

Regulatory and research status

Ipamorelin has no approved product licence in the United States or the European Union for any indication. Material sold to laboratories is typically labelled research use only and is not intended for human consumption, and US pharmacy compounding rules treat bulk substances that lack an approved drug listing or a USP monograph restrictively. These are regulatory classifications, not statements about biological activity, and this page does not offer legal advice.

Limits of the evidence

Four points summarise the state of the record: most findings come from rodents; the comparisons that do exist often involve other secretagogues rather than placebo alone; the single identified human trial was explicitly framed as proof of concept; and effects reported in one species or receptor context have not necessarily replicated in another, as the ferret comparison against anamorelin illustrated (Physiol Behav, 2024).

References

• Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus (The Journal of Pharmacology and Experimental Therapeutics, 2009)
• The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats (Growth Hormone & IGF Research, 2001)
• Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats (Neuro Endocrinology Letters, 2004)
• The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets (Physiology & Behavior, 2024)
• The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats (The Journal of Endocrinology, 2000)
• The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus (Animal Reproduction Science, 2024)
• Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro (Histology and Histopathology, 2002)
• Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients (International Journal of Colorectal Disease, 2014)